Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Aligos Therapeutics, Inc. (ALGS)
|
Add to portfolio |
|
|
|
| Price: |
$11.80
| | Metrics |
| OS: |
42.9
|
M
| |
-118
|
% ROE
|
| Market cap: |
$507
|
M
| |
|
|
|
Net cash:
|
$90.8
|
M
| |
$2.12
|
per share
|
|
EV:
|
$416
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
($1.92)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 0.0 | 0.0 | 0.0 | 55.9 |
| Revenue growth | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 55.9 |
| Gross margin | | | | 100.0% |
| Selling, general and administrative | 111.5 | 132.7 | 97.8 | |
| Research and development | | | | 44.0 |
| General and administrative | | | | 10.0 |
| EBIT | -111.5 | 0.0 | -107.6 | -54.0 |
| EBIT margin | | | | -96.7% |
| Pre-tax income | -95.9 | -128.2 | -108.4 | -52.2 |
| Income taxes | 0.1 | 0.1 | 0.2 | 0.1 |
| Net income | -96.0 | -128.3 | -108.5 | -52.3 |
| Net margin | | | | -93.5% |
| |
| Diluted EPS | ($2.25) | ($3.22) | ($10.87) | ($26.04) |
| Shares outstanding (diluted) | 42.7 | 39.9 | 10.0 | 2.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|